+ 0.89
+ 0.26%
+ 0.07
+ 0.02%
+ 0.75
+ 0.18%

Why Is It Moving? Looking At DAVIDsTEA's Price Action Today

May 5, 2021 2:01 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

DAVIDsTEA's Stock Price And Volume Action

DAVIDsTEA (NASDAQ:DTEA) is currently up 31.04% to a price of $4.1. The stock's current volume for the day is 1.27 million, which is approximately 766.28% of its previous 30-day average volume of 165.84 thousand.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: DAVIDsTEA shares are trading higher after the company announced it will seek court authorization for Companies' Creditors Arrangement Act.

Perspective On Recent Price Action

The 50-day moving average price of DAVIDsTEA's stock was $3.62 when this article was published. The stock reached a high of $7.45 and a low of $0.58 in the past 52 weeks.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Trading Ideas

Related Articles

62 Biggest Movers From Yesterday

Gainers read more

70 Biggest Movers From Yesterday

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd. read more

50 Stocks Moving In Wednesday's Mid-Day Session

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 64.9% to $7.75 after the company reported an order for 200,000 sugarBEAT sensors. read more

28 Stocks Moving in Wednesday's Pre-Market Session

Gainers Athenex, Inc. (NASDAQ: ATNX) shares rose 46.6% to $5.44 in pre-market trading after the company announced it acquired Kuur Therapeutics. read more